Autres langues Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE

Actions

TEVA

IL0006290147

Marché Fermé - TEL AVIV STOCK EXCHANGE Autres places de cotation 14:49:47 12/05/2024			Varia. 5j.	Varia. 1 janv.
6 030 ^ILa	+2,73 %		+17,18 %	+58,06 %

13/05	TEVA PHARMACEUTICAL INDUSTRIES LIMITED : Piper Sandler optimiste sur le dossier	ZM
09/05	En Direct des Marchés : Sabadell, TotalEnergies, Airbnb, ARM, Medincell, Nexi...

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-749 as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia	09/05
Teva Pharmaceutical Industries : Immediate Report	08/05
Sector Update: Health Care Stocks Slipping Wednesday Afternoon	08/05
Teva Pharmaceutical Shares Rise After Reporting Higher Q1 Earnings, Revenue; 2024 Guidance Reaffirmed	08/05
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday	08/05
Sector Update: Health Care	08/05
Teva Pharmaceutical Industries Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed	08/05
Earnings Flash (TEVA) TEVA PHARMACEUTICAL INDUSTRIES LIMITED Posts Q1 Revenue $3.82B	08/05
Earnings Flash (TEVA) TEVA PHARMACEUTICAL INDUSTRIES LIMITED Posts Q1 EPS $0.48	08/05
Teva Pharm Q1 profit falls short of estimates, revenue gains	08/05
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook	08/05
Teva Pharmaceutical Industries Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Teva Pharmaceutical Industries Limited Reports Impairment of Long-Lived Assets for the Three Months Ended March 31, 2024	08/05
Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2024	08/05
Teva's 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets	03/05
Teva to Present at the 2024 Bank of America Healthcare Conference	03/05
Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets	02/05
Alvotech - U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-FreeInterchangeable Biosimilar to Humira	01/05
HINTERGRUND/FTC knöpft sich Patentanmeldungen für Arzneimittel vor	01/05
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Teva Pharmaceutical Industries Limited : Doit encore lâcher du lest

Le 01 février 2024 à 10:03

INTERVIEW - Richard Francis, PDG de Teva Pharmaceutical : trimestre solide, prévisions annuelles relevées

Le 02 août 2023 à 21:19